Gender Disparities in Voice Outcomes After Tracheoesophageal Puncture in Total Laryngectomy Patients (UC Davis)

Gender Disparities in Voice Outcomes After Tracheoesophageal Puncture in Total Laryngectomy

To perform a multi-site prospective study assessing, both subjectively and objectively, the gender disparities in speech outcomes of patients using TEP after total laryngectomy.

The investigators hypothesize that speech outcomes, both subjective and objective measures, will be significantly poorer for female patients compared to male patients. The outcome of the study is to prospectively assess both subjective and objective gender disparities in voice and speech outcomes of patients using TEP after total laryngectomy across a multiple institutions. The investigators hypothesize that both subjective and objective measurements of voice, speech and quality of life will be poorer for female patients in comparison to male patients.

Study Overview

• Status: Recruiting
• Conditions: Speech Disorders; Laryngectomy; Status; Total Laryngectomy; Speech Dysfunction; Tracheoesophageal Prosthesis

Detailed Description

Total laryngectomy (TL) is typically performed in patients with advanced laryngeal cancer as a means of removing the entire larynx and surrounding structures that have been affected by the malignancy. Following total laryngectomy, patients lose ability to produce voice. Thus, they require the use of alternative methods of to produce voice along with extensive speech rehabilitation. Currently, there are three main speech alternative options, esophageal speech, tracheoesophageal speech, and electrolarynx speech. The focus of this study will be on patients rehabilitating their speech using tracheosophgeal speech through a tracheoesophageal prosthesis (TEP). It has been shown that generally for TL patients, better voice quality and satisfaction with voice is associated with improved quality of life. Currently, speech rehabilitation outcomes are measured with a multidimensional approach, using various scales ranging from acoustic analysis, perceptual evaluation, and patient-reported outcomes. The majority of studies analyzing outcomes in total laryngectomy patients, however, is predominated by assessment of the male laryngectomee population. Historically, this has been due to the greater incidence of laryngeal cancers in males than females. Due to this, there has been minimal research investigating potential gender differences in the laryngectomy population. Of the limited data available regarding the female laryngectomee population, it has been shown that gender frequency differences seen in normal subjects are lost following total laryngectomy and the resulting tracheoesophageal voice is more similar to the normal male voice, thus females face a greater voice handicap compared to their male counterparts (Kazi, 2006; Deore, 2011). While some studies have assessed the resulting quality of life differences between the genders in the laryngectomy population (Lee, 2010), few have investigated voice outcomes using both subjective and objective scales as used in this study. The outcomes of this study will be key to understanding what metrics are potentially contributing to the voice and lifestyle dissatisfaction that prior studies have demonstrated in the female laryngectomee population. This quantifiable data will provide a way of modifying future voice rehabilitation in the female population to enable better satisfaction and minimize gender differences in voice outcomes.

• Study Type: Observational
• Enrollment (Estimated): 12

Contacts and Locations

• Study Contact: Name: Jasmine Cate; Phone Number: 8582463035; Email: jcate@health.ucsd.edu
• Study Contact Backup: Name: Debanjali Ghosh; Phone Number: 858.246.0357; Email: d1ghosh@health.ucsd.edu

Study Locations

• United States
  • California
    • La Jolla, California, United States, 92093
      • Recruiting
      • University of California San Diego
      • Contact: Kristen Linnemeyer, CCC-SLP, BCS-S; Email: klinnemeyer@health.ucsd.edu
      • Contact: Kayleigh N Hernandez, BS; Phone Number: (858) 246-0357; Email: knhernandez@health.ucsd.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

patients with advanced laryngeal cancer who have completed total laryngectomy requiring use of alternative methods to produce voice along with extensive speech rehabilitation.

Description

Inclusion Criteria:

• Male and female subjects who have completed total laryngectomy and are using TEP

Exclusion Criteria:

• Subjects who have not completed total laryngectomy and are not using TEP

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Other

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
FACT-H&N (Functional Assessment of Cancer Therapy - Head & Neck)	Patient reported survey.	Through study completion; 3 years (anticipate completion by June 2025)
AVHI (Alaryngeal Voice Handicap Index)	Patient reported survey.	Through study completion; 3 years (anticipate completion by June 2025)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
GRBAS - Grade, Roughness, Breathiness, Asthenia, and Strain	Examiner-based interpretation of roughness/breathiness of patient's voice. Scale of 0-3, 3 indicating severe, 0 indicating normal	Through study completion; 3 years (anticipate completion by June 2025)
Sustained phonation time	A measurement in seconds of how long a patient can sustain phonation.	Through study completion; 3 years (anticipate completion by June 2025)
Fundamental frequency	A measurement of frequency of voice during alaryngeal speech/sustained phonation	Through study completion; 3 years (anticipate completion by June 2025)

Collaborators and Investigators

• Sponsor: University of California, Davis
• Collaborators: University of California, San Diego

Study record dates

Study Major Dates

• Study Start (Actual): May 31, 2023
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026

Study Registration Dates

• First Submitted: July 28, 2022
• First Submitted That Met QC Criteria: August 3, 2022
• First Posted (Actual): August 5, 2022

Study Record Updates

• Last Update Posted (Actual): February 11, 2026
• Last Update Submitted That Met QC Criteria: February 9, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Neurobehavioral Manifestations; Communication Disorders; Language Disorders; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Speech Disorders
• Other Study ID Numbers: 1509981

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No